Back to Results
First PageMeta Content
Interstitial cystitis / Robert S. Langer / Pfizer / Urology / Chronic prostatitis/chronic pelvic pain syndrome / Cystitis / Medicine / Health / Taris


TARIS Appoints Christopher Searcy as the Company’s Chief Business Officer Lexington, MA – July 25 , 2011 – TARIS Biomedical®, a specialty pharmaceutical company pioneering the development of innovative, targeted
Add to Reading List

Document Date: 2011-07-25 07:48:57

Open Document

File Size: 119,34 KB

Share Result on Facebook

Company

Flagship Ventures / Pfizer Inc. / Galagen Inc. / Pfizer International / Valeritas Inc. / Flybridge Capital Partners / TARIS Biomedical / Third Rock Ventures / Polaris Venture Partners / Inhale/Nektar Therapeutics / /

Country

United States / /

Event

Employment Change / /

Facility

University of Minnesota / Massachusetts Institute of Technology / University of Pennsylvania / /

IndustryTerm

venture capital / treatment of bladder diseases / biotechnology / technology platforms / pharmaceutical / late-stage specialty pharmaceutical / /

MedicalCondition

bladder diseases / overactive bladder / Bladder Disease Bladder diseases / bladder cancer / interstitial cystitis / chronic pelvic pain syndrome / diseases / bladder syndrome / urinary tract infections / disorders / /

Organization

Wharton School / the University of Pennsylvania / Massachusetts Institute of Technology / University of Minnesota / /

Person

Lexington / Christopher Searcy / Robert Langer / Sarma Duddu / Michael Cima / /

Position

Director of Licensing and Development / leader / President and CEO / Chief Business Officer / Vice President of Business Development / Senior Vice President of Corporate and Business Development / Vice President of Corporate Development / VP of Corporate Development / /

ProvinceOrState

Minnesota / Pennsylvania / Massachusetts / /

Technology

drug delivery / biotechnology / /

URL

www.tarisbiomedical.com / /

SocialTag